{"ticker": {"uuid": "78a77a16-cd81-4548-bfc7-ae6ef81d514c", "symbol": "ABVC", "name": "ABVC Biopharma Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ABVC BioPharma (ABVC) replaces auditor and reiterates going-concern language", "summary": "ABVC BioPharma (ABVC) announced a change in its independent auditor, dismissing Simon & Edward, LLP and engaging Kreit & Chiu CPA LLP for the fiscal year ending December 31, 2026. The company noted that previous audit reports included \"going-concern\" language and material weaknes", "url": "https://www.stocktitan.net/sec-filings/ABVC/8-k-abvc-biopharma-inc-reports-material-event-90f6cda08acc.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:02:08", "published_display": "02 Jul 2026 20:02", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ABVC BioPharma, Inc. \u2013 NASDAQ:ABVC", "summary": "This article provides financial information for ABVC BioPharma, Inc. (NASDAQ:ABVC), specifically focusing on its price-to-book forward ratio. It highlights that the market for ABVC is currently closed with no trades. The article is hosted on TradingView, a financial platform offe", "url": "https://www.tradingview.com/symbols/NASDAQ-ABVC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:09:41", "published_display": "27 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ABVC BioPharma, Inc. \u2013 NASDAQ:ABVC", "summary": "This article presents the \"Price to sales forward\" metric for ABVC BioPharma, Inc. (NASDAQ: ABVC). It focuses solely on this financial data point for the company, accessible through the TradingView platform. The content is essentially a data display, without further analysis or e", "url": "https://www.tradingview.com/symbols/NASDAQ-ABVC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T23:10:34", "published_display": "26 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Should I Buy", "summary": "An analysis of ABVC Biopharma Inc. (ABVC) suggests it is not a strong buy for long-term investors despite some short-term bullish momentum. Key concerns include a lack of supporting news, recent financial updates, analyst upgrades, or significant insider/hedge fund accumulation. ", "url": "https://intellectia.ai/en/stock/ABVC/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-06-26T18:10:48", "published_display": "26 Jun 2026 18:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of ABVC BioPharma, Inc. \u2013 NASDAQ:ABVC", "summary": "This article displays the enterprise value to EBITDA forward for ABVC BioPharma, Inc. (NASDAQ:ABVC) as presented on TradingView. The page shows the company's stock market information, financial data, and other related services offered by TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-ABVC/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:12:27", "published_display": "26 Jun 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma, Inc. Actuals & Estimates (NASDAQ:ABVC)", "summary": "This article provides an overview of ABVC BioPharma, Inc. (NASDAQ: ABVC) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, such as net income for the last quarter and the upcoming earnings report date. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-ABVC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:09:27", "published_display": "25 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders", "summary": "ABVC BioPharma (ABVC) plans to spin off its subsidiary, BioKey (Cayman), Inc., to ABVC shareholders through a dividend distribution. This strategic move aims to unlock shareholder value by separating the two distinct businesses, potentially allowing both entities to pursue indepe", "url": "https://news.futunn.com/en/post/75009974/abvc-biopharma-inc-announces-planned-spin-off-of-biokey-cayman?futusource=news_newspage_recommend", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-24T08:12:21", "published_display": "24 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Net Loss of $0.06 Per Share as Stock Rises 1.53% Amid No Reported Revenue - Forward Guidance Trends", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPdU8wb2RIY1pfU09Na3ZXSlk4RG5YR0JwRHVNU3BEUWFISk5ZMVRja2FTM0dLZDk4akhQeFZoOHpFcVotMER6eHB2LU1EbkhMUXZfTkZlbGpZMFlPN0E0Q3A5R3Y0WE0yeUNleDY0dVkzY0cyeFF5eVU4bHdkMzVRNHluaEtrRGZQeU5VR3pIWFJjbUdBOV9EbmFYcHBzQXp3RjUwMGIyVS1mSThhM2o0M1ctdnJEOWJGY1dRV2F5RnVfeGpCMkpaeF9Jdnc2UHg4b3VaT3hFeW92TUZLaEFZZ2twUkpQUmVmZUJJ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for ABVC Biopharma Inc (ABVC), noting that no specific earnings forecast score is currently available for the company, contrasting with the Biotechnology & Medical Research industry's average score of 8.13. It also states that relevant f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T18:09:27", "published_display": "19 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of ABVC Biopharma Inc (ABVC), listing major individual and corporate shareholders along with their proportions. It also presents a breakdown of shareholder types and institutional holdings over several quarters, showing changes in th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T11:39:54", "published_display": "18 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Institutional Confidence", "summary": "ABVC Biopharma Inc (ABVC) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.41%, indicating a quarter-over-quarter increase of 1.88%. James Simons is", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:49", "published_display": "18 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses ABVC Biopharma Inc (ABVC) and its revenue breakdown by business segments and regional contributions. However, it explicitly states that the relevant financial data for these categories has not yet been disclosed by the company. Therefore, while the topic is ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:49", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of ABVC Biopharma Inc (ABVC), detailing its current price momentum score of 8.79 within the Biotechnology & Medical Research industry. It identifies key support and resistance levels for the stock, suitable for range-bound swing trading.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/technical", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:49", "published_display": "18 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of ABVC Biopharma Inc (ABVC) as of June 18, 2026, ranking its financial score at 8.03, which is 71 out of 389 in the Biotechnology & Medical Research industry. It highlights that the company's financial status is weak but operatin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:53", "published_display": "18 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of ABVC Biopharma Inc (ABVC), noting its current valuation score of 6.23, which ranks it low within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -3.41, which is significantly below its r", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:49", "published_display": "18 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of ABVC Biopharma Inc.'s (ABVC) dividend history and stock split events. It indicates that the company has not distributed any dividends over the past five years and details a series of 10-for-1 merger-related stock splits that occurred on July 2", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-16T07:41:00", "published_display": "16 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC - ABVC BioPharma Inc Stock Price and Quote", "summary": "This article provides comprehensive stock information for ABVC BioPharma Inc., including its latest closing price, financial metrics, insider ownership, and performance indicators. It also lists recent news and press releases detailing the company's strategic initiatives, licensi", "url": "https://finviz.com/stock?t=ABVC", "source_name": "Finviz", "published_at": "2026-06-04T21:40:57", "published_display": "04 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Thursday's Pre-Market Session", "summary": "This article lists 12 healthcare stocks experiencing significant price movements in Thursday's pre-market session. SciSparc, BioLine Rx, Propanc Biopharma, CytoSorbents, ABVC BioPharma, and Cumberland Pharma saw gains, while ADC Therapeutics, Basel Medical Group, Picard Medical, ", "url": "https://www.benzinga.com/insights/movers/26/06/52996353/12-health-care-stocks-moving-in-thursdays-pre-market-session", "source_name": "Benzinga", "published_at": "2026-06-04T12:09:21", "published_display": "04 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC PE Ratio & Valuation, Is ABVC Overvalued", "summary": "ABVC Biopharma Inc. (ABVC) is currently considered undervalued, with its forward PS ratio of 0.00 significantly lower than its five-year average of -3.14. Its fair price is estimated to be between +Inf and +Inf according to a relative valuation method. The company's Price-to-Book", "url": "https://intellectia.ai/en/stock/ABVC/valuation", "source_name": "Intellectia AI", "published_at": "2026-06-03T02:09:16", "published_display": "03 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma, Inc. 1Q 2026: Revenue ($1.55M), Net income ($1.56M), EPS ($0.06) \u2014 10-Q Summary", "summary": "ABVC BioPharma, Inc. reported a larger comprehensive and net loss in Q1 2026 compared to the prior year. The company is advancing multiple clinical programs and investing in manufacturing and CDMO capacity, but also faced an operational setback with its Vitargus\u00ae Phase II trial b", "url": "https://www.tradingview.com/news/tradingview:8d3c3a3b93854:0-abvc-biopharma-inc-1q-2026-revenue-1-55m-net-income-1-56m-eps-0-06-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-18T11:10:24", "published_display": "18 May 2026 11:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma (NASDAQ: ABVC) posts Q1 loss and going concern warning", "summary": "ABVC BioPharma reported a Q1 2026 net loss of $1.69 million, an increase from $0.94 million a year prior, primarily due to higher operating expenses. The company's cash and cash equivalents significantly decreased to $140,324, and it reported a working capital deficit of $4.74 mi", "url": "https://www.stocktitan.net/sec-filings/ABVC/10-q-abvc-biopharma-inc-quarterly-earnings-report-76b99692fdf5.html", "source_name": "Stock Titan", "published_at": "2026-05-18T11:10:24", "published_display": "18 May 2026 11:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC: Q1 2026 saw a $1.69M net loss, no revenue, and a $4.74M working capital deficit", "summary": "ABVC BioPharma, Inc. (ABVC) reported a net loss of $1.69 million in Q1 2026, marking a 79% increase year-over-year, with no revenue generated. The company also faced a working capital deficit of $4.74 million. Management is focusing on improving liquidity, debt reduction, and lev", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3343362:0-abvc-q1-2026-saw-a-1-69m-net-loss-no-revenue-and-a-4-74m-working-capital-deficit/", "source_name": "TradingView", "published_at": "2026-05-18T11:10:24", "published_display": "18 May 2026 11:10", "sentiment": "negative", "sentiment_pct": 14, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma Delays Quarterly SEC Filing", "summary": "ABVC BioPharma announced a delay in filing its Form 10-Q (Quarter Report) for the quarter ending March 31, 2026, due to timing and workload issues, but expects to file within the SEC grace period. The company does not anticipate significant changes in operating results compared t", "url": "https://www.tipranks.com/news/company-announcements/abvc-biopharma-delays-quarterly-sec-filing", "source_name": "TipRanks", "published_at": "2026-05-16T01:39:13", "published_display": "16 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC (ABVC) files Form 12b-25: late 10-Q for March 31, 2026", "summary": "ABVC BioPharma, Inc. has filed a Form 12b-25 with the SEC, indicating that it will be submitting its Form 10-Q for the period ended March 31, 2026, late. The company stated that it could not finalize the XBRL exhibit without \"unreasonable effort or expense\" but expects to file wi", "url": "https://www.stocktitan.net/sec-filings/ABVC/nt-10-q-abvc-biopharma-inc-sec-filing-3946d3e515a4.html", "source_name": "Stock Titan", "published_at": "2026-05-15T21:10:12", "published_display": "15 May 2026 21:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TradingKey", "summary": "The article provides a market overview for ABVC Biopharma Inc. (ABVC), showing its stock price, market capitalization, and a prompt for user comments. It also highlights the platform's features like financial data, analysis tools, and various market categories presented by Tradin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/comments", "source_name": "TradingKey", "published_at": "2026-05-11T23:40:01", "published_display": "11 May 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ABVC Options Chain \u2014 NASDAQ:ABVC", "summary": "This page provides an options chain for ABVC BioPharma, Inc. (NASDAQ:ABVC), allowing users to track market movements and assess risks for call and put options. It displays live pricing, Greeks, implied volatility, and other key metrics for various expiration dates and strike pric", "url": "https://www.tradingview.com/symbols/NASDAQ-ABVC/options-chain/", "source_name": "TradingView \u2014 Track All Markets", "published_at": "2026-04-12T13:40:18", "published_display": "12 Apr 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Options Volatility \u2014 NASDAQ:ABVC", "summary": "This article from TradingView provides an overview of ABVC BioPharma, Inc.'s options volatility. It focuses on implied volatility curves and at-the-money implied volatility across different expiration dates to help traders assess risks and craft options strategies based on market", "url": "https://www.tradingview.com/symbols/NASDAQ-ABVC/options-volatility/", "source_name": "TradingView \u2014 Track All Markets", "published_at": "2026-04-12T13:40:18", "published_display": "12 Apr 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Monday's Intraday Session - ABVC BioPharma (NASDAQ:ABVC), Aditxt (NASDAQ", "summary": "This article lists 12 health care stocks that experienced significant movement during Monday's intraday trading session. It highlights both gainers, such as Profusa (NASDAQ:PFSA) and IO Biotech (NASDAQ:IOBT), and losers, including Akari Therapeutics (NASDAQ:AKTX) and Viridian The", "url": "https://www.benzinga.com/insights/movers/26/04/51664137/12-health-care-stocks-moving-in-mondays-intraday-session", "source_name": "Benzinga", "published_at": "2026-04-06T17:11:47", "published_display": "06 Apr 2026 17:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Stock News Today | Earnings, Events & Price Alerts", "summary": "This article provides recent news and event updates for ABVC BioPharma, Inc. (ABVC), focusing on its financial activities, licensing agreements, and progress in clinical trials. Key events include securing licensing payments for oncology and psychiatric disorder products, signifi", "url": "https://intellectia.ai/en/stock/ABVC/news", "source_name": "Intellectia AI", "published_at": "2026-04-01T10:09:25", "published_display": "01 Apr 2026 10:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOQVF0bVdqVFZfVXUzS1M4eVNGZW1PaHRESXNlMllEWlpkcFV1SWhUa1NMUDBKc0NTMzdnUl9VU3lkREJpY3RvOENrWEJULUl4b0c2MmlLYjF4dUp6aHBqVHlwZVRKNlRyZ3kxTzVTU25IMWtMY09MLS1LWWFRMTRkMlpHQ0hfamZ3NWFz?oc=5", "source_name": "Market source", "published_at": "2025-08-26T07:00:00+00:00", "published_display": "26 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNXzBKR1hRRkpnVXRTbzJOcW0yNmZhcElPMkZ5bTQ3MzdmcjhKazFaWXotc2pyaW1wYS1sdW90TWtpclZ5a3VwY25FeXY0XzctOFh6TXBQemxvVWVfSm5yZGlTQVo4YzJoUVp4Y25pZDI3ckVFV3lSZHRvSVNpUHVQQkdFWE1fYXAtLXNxZQ?oc=5", "source_name": "Market source", "published_at": "2025-06-24T07:00:00+00:00", "published_display": "24 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE54TWd3R25YaVlqak4wbzJwRVRxaktiNmYtZUNLQzZUSmUxdUdzX2RDVG1vZk52UkF2Ym9qM1g4ZmMzMzhuZWhPTGJYX2w1QzVuUkhJ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:27:19+00:00", "published_display": "24 Apr 2025 23:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma (ABVC) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9QXy1fY0J4Y3lGRTNGVWFDWXNQbUc1emdQeFJfamFSN2h3LUx6QnRjcFZLQ2hwNkFwVzYwdl95TXJmcUNhWHdwUFBRODJDY0Fvd1pnRDB0aHVqQjdwTExDUUhXSzgyZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:01:55+00:00", "published_display": "11 May 2024 15:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOMXMtR3pjbUZYaXNLT2JhRXVqekczdFhBc0lFbjFubzU5V1hYeHZSZzJldmlvX19WTVE4Ti12a0RlX2xscHRvdlhVdUZ3aHZLNF9DNFRfV2s4TG82VFduT3U0SjdxV0hHZ0RCNG14SnBCYnlOeDVNeTZfV1ZrMmphSDljMA?oc=5", "source_name": "Market source", "published_at": "2024-04-18T07:00:00+00:00", "published_display": "18 Apr 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma on the path to validating traditional medicine for the modern world", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQmxKSmtRcWtiMkxUTEtoem9tZWlQaUxDWHdrblVPbzd1X05OUGdTUmZoN2FhX0VhNUtPdTNsektJVkxvTC1PYXZZTGt1SmVRY2JaOUh6eklmUGlFcThVbkpTeTZHT0oyRzROa1VwbWRnTGFQRFRtZ2x4Mkh0NFMtWjNIZXBpMjY3N1B1dFFzeVhVckNmbUVUTjE5RG9sLVppdGNrM0lzYU9FZEh4MmFkbXBxcHZrajc1VHVPbVZnU0I?oc=5", "source_name": "BioWorld News", "published_at": "2023-01-25T08:00:00+00:00", "published_display": "25 Jan 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for ABVC BIOPHARMA (ABVC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9jelVnekdXYzBxUk9hMTJXR1RqRjVMeDg0WVIzbWhFVk9rZ090d1U0bnZRdXVsb19kVXdBSDZTclRPeURKMHp2SHFwdnM3cFdGUTV6UElrTDFfcUE3T0pjamtmdWdLTFYzMzZCSVNjOExiaEM4YXBKRg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-11-11T18:11:34+00:00", "published_display": "11 Nov 2022 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma (ABVC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5PTWtlLVVYbGozQzlSOE5IUzk3QmdzMFRQZ2kyWXBNYXQ2RUZXRklHNFFEMHViU19taHl0Y0M0MVRoYUlDSmNXRi1sT0lvOFFDdFdYU3cwNlB5dw?oc=5", "source_name": "MarketBeat", "published_at": "2021-09-14T21:04:03+00:00", "published_display": "14 Sep 2021 21:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abvc Biopharma Stock Price Forecast. Should You Buy ABVC?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE1oUFVxeHllSW81dFBIbHNYT0p2SlNkQjVuYzIyYWVDY2dMaWpIX1liaktOS2ZkSVNwVlF2YW1oVndsRGVmclJKXw?oc=5", "source_name": "StockInvest.us", "published_at": "2021-08-12T16:46:56+00:00", "published_display": "12 Aug 2021 16:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Stock Price and Chart \u2014 NASDAQ:ABVC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9BYkZiNXR0VGVWUDdsUkdhTkFTQVdlREljUkFEbUdHa3Rzc3BOcVBwblY5aG9SY1NXTlY3TnI3dUJfOVI4MnlMXzJKUWgwbjcyZ3p5UzF0U0g1eGF5?oc=5", "source_name": "TradingView", "published_at": "2021-08-04T10:05:36+00:00", "published_display": "04 Aug 2021 10:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ABVC BioPharma (ABVC) replaces auditor and reiterates going-concern language", "summary": "ABVC BioPharma (ABVC) announced a change in its independent auditor, dismissing Simon & Edward, LLP and engaging Kreit & Chiu CPA LLP for the fiscal year ending December 31, 2026. The company noted that previous audit reports included \"going-concern\" language and material weaknes", "url": "https://www.stocktitan.net/sec-filings/ABVC/8-k-abvc-biopharma-inc-reports-material-event-90f6cda08acc.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:02:08", "published_display": "02 Jul 2026 20:02", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ABVC BioPharma, Inc. \u2013 NASDAQ:ABVC", "summary": "This article provides financial information for ABVC BioPharma, Inc. (NASDAQ:ABVC), specifically focusing on its price-to-book forward ratio. It highlights that the market for ABVC is currently closed with no trades. The article is hosted on TradingView, a financial platform offe", "url": "https://www.tradingview.com/symbols/NASDAQ-ABVC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:09:41", "published_display": "27 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ABVC BioPharma, Inc. \u2013 NASDAQ:ABVC", "summary": "This article presents the \"Price to sales forward\" metric for ABVC BioPharma, Inc. (NASDAQ: ABVC). It focuses solely on this financial data point for the company, accessible through the TradingView platform. The content is essentially a data display, without further analysis or e", "url": "https://www.tradingview.com/symbols/NASDAQ-ABVC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T23:10:34", "published_display": "26 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Should I Buy", "summary": "An analysis of ABVC Biopharma Inc. (ABVC) suggests it is not a strong buy for long-term investors despite some short-term bullish momentum. Key concerns include a lack of supporting news, recent financial updates, analyst upgrades, or significant insider/hedge fund accumulation. ", "url": "https://intellectia.ai/en/stock/ABVC/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-06-26T18:10:48", "published_display": "26 Jun 2026 18:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of ABVC BioPharma, Inc. \u2013 NASDAQ:ABVC", "summary": "This article displays the enterprise value to EBITDA forward for ABVC BioPharma, Inc. (NASDAQ:ABVC) as presented on TradingView. The page shows the company's stock market information, financial data, and other related services offered by TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-ABVC/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:12:27", "published_display": "26 Jun 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma, Inc. Actuals & Estimates (NASDAQ:ABVC)", "summary": "This article provides an overview of ABVC BioPharma, Inc. (NASDAQ: ABVC) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, such as net income for the last quarter and the upcoming earnings report date. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-ABVC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:09:27", "published_display": "25 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders", "summary": "ABVC BioPharma (ABVC) plans to spin off its subsidiary, BioKey (Cayman), Inc., to ABVC shareholders through a dividend distribution. This strategic move aims to unlock shareholder value by separating the two distinct businesses, potentially allowing both entities to pursue indepe", "url": "https://news.futunn.com/en/post/75009974/abvc-biopharma-inc-announces-planned-spin-off-of-biokey-cayman?futusource=news_newspage_recommend", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-24T08:12:21", "published_display": "24 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Net Loss of $0.06 Per Share as Stock Rises 1.53% Amid No Reported Revenue - Forward Guidance Trends", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPdU8wb2RIY1pfU09Na3ZXSlk4RG5YR0JwRHVNU3BEUWFISk5ZMVRja2FTM0dLZDk4akhQeFZoOHpFcVotMER6eHB2LU1EbkhMUXZfTkZlbGpZMFlPN0E0Q3A5R3Y0WE0yeUNleDY0dVkzY0cyeFF5eVU4bHdkMzVRNHluaEtrRGZQeU5VR3pIWFJjbUdBOV9EbmFYcHBzQXp3RjUwMGIyVS1mSThhM2o0M1ctdnJEOWJGY1dRV2F5RnVfeGpCMkpaeF9Jdnc2UHg4b3VaT3hFeW92TUZLaEFZZ2twUkpQUmVmZUJJ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for ABVC Biopharma Inc (ABVC), noting that no specific earnings forecast score is currently available for the company, contrasting with the Biotechnology & Medical Research industry's average score of 8.13. It also states that relevant f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T18:09:27", "published_display": "19 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of ABVC Biopharma Inc (ABVC), listing major individual and corporate shareholders along with their proportions. It also presents a breakdown of shareholder types and institutional holdings over several quarters, showing changes in th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T11:39:54", "published_display": "18 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Institutional Confidence", "summary": "ABVC Biopharma Inc (ABVC) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.41%, indicating a quarter-over-quarter increase of 1.88%. James Simons is", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:49", "published_display": "18 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses ABVC Biopharma Inc (ABVC) and its revenue breakdown by business segments and regional contributions. However, it explicitly states that the relevant financial data for these categories has not yet been disclosed by the company. Therefore, while the topic is ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:49", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of ABVC Biopharma Inc (ABVC), detailing its current price momentum score of 8.79 within the Biotechnology & Medical Research industry. It identifies key support and resistance levels for the stock, suitable for range-bound swing trading.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/technical", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:49", "published_display": "18 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of ABVC Biopharma Inc (ABVC) as of June 18, 2026, ranking its financial score at 8.03, which is 71 out of 389 in the Biotechnology & Medical Research industry. It highlights that the company's financial status is weak but operatin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:53", "published_display": "18 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of ABVC Biopharma Inc (ABVC), noting its current valuation score of 6.23, which ranks it low within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -3.41, which is significantly below its r", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:49", "published_display": "18 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma Inc (ABVC) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of ABVC Biopharma Inc.'s (ABVC) dividend history and stock split events. It indicates that the company has not distributed any dividends over the past five years and details a series of 10-for-1 merger-related stock splits that occurred on July 2", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-16T07:41:00", "published_display": "16 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC - ABVC BioPharma Inc Stock Price and Quote", "summary": "This article provides comprehensive stock information for ABVC BioPharma Inc., including its latest closing price, financial metrics, insider ownership, and performance indicators. It also lists recent news and press releases detailing the company's strategic initiatives, licensi", "url": "https://finviz.com/stock?t=ABVC", "source_name": "Finviz", "published_at": "2026-06-04T21:40:57", "published_display": "04 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Thursday's Pre-Market Session", "summary": "This article lists 12 healthcare stocks experiencing significant price movements in Thursday's pre-market session. SciSparc, BioLine Rx, Propanc Biopharma, CytoSorbents, ABVC BioPharma, and Cumberland Pharma saw gains, while ADC Therapeutics, Basel Medical Group, Picard Medical, ", "url": "https://www.benzinga.com/insights/movers/26/06/52996353/12-health-care-stocks-moving-in-thursdays-pre-market-session", "source_name": "Benzinga", "published_at": "2026-06-04T12:09:21", "published_display": "04 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC PE Ratio & Valuation, Is ABVC Overvalued", "summary": "ABVC Biopharma Inc. (ABVC) is currently considered undervalued, with its forward PS ratio of 0.00 significantly lower than its five-year average of -3.14. Its fair price is estimated to be between +Inf and +Inf according to a relative valuation method. The company's Price-to-Book", "url": "https://intellectia.ai/en/stock/ABVC/valuation", "source_name": "Intellectia AI", "published_at": "2026-06-03T02:09:16", "published_display": "03 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma, Inc. 1Q 2026: Revenue ($1.55M), Net income ($1.56M), EPS ($0.06) \u2014 10-Q Summary", "summary": "ABVC BioPharma, Inc. reported a larger comprehensive and net loss in Q1 2026 compared to the prior year. The company is advancing multiple clinical programs and investing in manufacturing and CDMO capacity, but also faced an operational setback with its Vitargus\u00ae Phase II trial b", "url": "https://www.tradingview.com/news/tradingview:8d3c3a3b93854:0-abvc-biopharma-inc-1q-2026-revenue-1-55m-net-income-1-56m-eps-0-06-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-18T11:10:24", "published_display": "18 May 2026 11:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma (NASDAQ: ABVC) posts Q1 loss and going concern warning", "summary": "ABVC BioPharma reported a Q1 2026 net loss of $1.69 million, an increase from $0.94 million a year prior, primarily due to higher operating expenses. The company's cash and cash equivalents significantly decreased to $140,324, and it reported a working capital deficit of $4.74 mi", "url": "https://www.stocktitan.net/sec-filings/ABVC/10-q-abvc-biopharma-inc-quarterly-earnings-report-76b99692fdf5.html", "source_name": "Stock Titan", "published_at": "2026-05-18T11:10:24", "published_display": "18 May 2026 11:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC: Q1 2026 saw a $1.69M net loss, no revenue, and a $4.74M working capital deficit", "summary": "ABVC BioPharma, Inc. (ABVC) reported a net loss of $1.69 million in Q1 2026, marking a 79% increase year-over-year, with no revenue generated. The company also faced a working capital deficit of $4.74 million. Management is focusing on improving liquidity, debt reduction, and lev", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3343362:0-abvc-q1-2026-saw-a-1-69m-net-loss-no-revenue-and-a-4-74m-working-capital-deficit/", "source_name": "TradingView", "published_at": "2026-05-18T11:10:24", "published_display": "18 May 2026 11:10", "sentiment": "negative", "sentiment_pct": 14, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma Delays Quarterly SEC Filing", "summary": "ABVC BioPharma announced a delay in filing its Form 10-Q (Quarter Report) for the quarter ending March 31, 2026, due to timing and workload issues, but expects to file within the SEC grace period. The company does not anticipate significant changes in operating results compared t", "url": "https://www.tipranks.com/news/company-announcements/abvc-biopharma-delays-quarterly-sec-filing", "source_name": "TipRanks", "published_at": "2026-05-16T01:39:13", "published_display": "16 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC (ABVC) files Form 12b-25: late 10-Q for March 31, 2026", "summary": "ABVC BioPharma, Inc. has filed a Form 12b-25 with the SEC, indicating that it will be submitting its Form 10-Q for the period ended March 31, 2026, late. The company stated that it could not finalize the XBRL exhibit without \"unreasonable effort or expense\" but expects to file wi", "url": "https://www.stocktitan.net/sec-filings/ABVC/nt-10-q-abvc-biopharma-inc-sec-filing-3946d3e515a4.html", "source_name": "Stock Titan", "published_at": "2026-05-15T21:10:12", "published_display": "15 May 2026 21:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TradingKey", "summary": "The article provides a market overview for ABVC Biopharma Inc. (ABVC), showing its stock price, market capitalization, and a prompt for user comments. It also highlights the platform's features like financial data, analysis tools, and various market categories presented by Tradin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abvc/comments", "source_name": "TradingKey", "published_at": "2026-05-11T23:40:01", "published_display": "11 May 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Options Chain \u2014 NASDAQ:ABVC", "summary": "This page provides an options chain for ABVC BioPharma, Inc. (NASDAQ:ABVC), allowing users to track market movements and assess risks for call and put options. It displays live pricing, Greeks, implied volatility, and other key metrics for various expiration dates and strike pric", "url": "https://www.tradingview.com/symbols/NASDAQ-ABVC/options-chain/", "source_name": "TradingView \u2014 Track All Markets", "published_at": "2026-04-12T13:40:18", "published_display": "12 Apr 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Options Volatility \u2014 NASDAQ:ABVC", "summary": "This article from TradingView provides an overview of ABVC BioPharma, Inc.'s options volatility. It focuses on implied volatility curves and at-the-money implied volatility across different expiration dates to help traders assess risks and craft options strategies based on market", "url": "https://www.tradingview.com/symbols/NASDAQ-ABVC/options-volatility/", "source_name": "TradingView \u2014 Track All Markets", "published_at": "2026-04-12T13:40:18", "published_display": "12 Apr 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Monday's Intraday Session - ABVC BioPharma (NASDAQ:ABVC), Aditxt (NASDAQ", "summary": "This article lists 12 health care stocks that experienced significant movement during Monday's intraday trading session. It highlights both gainers, such as Profusa (NASDAQ:PFSA) and IO Biotech (NASDAQ:IOBT), and losers, including Akari Therapeutics (NASDAQ:AKTX) and Viridian The", "url": "https://www.benzinga.com/insights/movers/26/04/51664137/12-health-care-stocks-moving-in-mondays-intraday-session", "source_name": "Benzinga", "published_at": "2026-04-06T17:11:47", "published_display": "06 Apr 2026 17:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Stock News Today | Earnings, Events & Price Alerts", "summary": "This article provides recent news and event updates for ABVC BioPharma, Inc. (ABVC), focusing on its financial activities, licensing agreements, and progress in clinical trials. Key events include securing licensing payments for oncology and psychiatric disorder products, signifi", "url": "https://intellectia.ai/en/stock/ABVC/news", "source_name": "Intellectia AI", "published_at": "2026-04-01T10:09:25", "published_display": "01 Apr 2026 10:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOQVF0bVdqVFZfVXUzS1M4eVNGZW1PaHRESXNlMllEWlpkcFV1SWhUa1NMUDBKc0NTMzdnUl9VU3lkREJpY3RvOENrWEJULUl4b0c2MmlLYjF4dUp6aHBqVHlwZVRKNlRyZ3kxTzVTU25IMWtMY09MLS1LWWFRMTRkMlpHQ0hfamZ3NWFz?oc=5", "source_name": "Market source", "published_at": "2025-08-26T07:00:00+00:00", "published_display": "26 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNXzBKR1hRRkpnVXRTbzJOcW0yNmZhcElPMkZ5bTQ3MzdmcjhKazFaWXotc2pyaW1wYS1sdW90TWtpclZ5a3VwY25FeXY0XzctOFh6TXBQemxvVWVfSm5yZGlTQVo4YzJoUVp4Y25pZDI3ckVFV3lSZHRvSVNpUHVQQkdFWE1fYXAtLXNxZQ?oc=5", "source_name": "Market source", "published_at": "2025-06-24T07:00:00+00:00", "published_display": "24 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE54TWd3R25YaVlqak4wbzJwRVRxaktiNmYtZUNLQzZUSmUxdUdzX2RDVG1vZk52UkF2Ym9qM1g4ZmMzMzhuZWhPTGJYX2w1QzVuUkhJ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:27:19+00:00", "published_display": "24 Apr 2025 23:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma (ABVC) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9QXy1fY0J4Y3lGRTNGVWFDWXNQbUc1emdQeFJfamFSN2h3LUx6QnRjcFZLQ2hwNkFwVzYwdl95TXJmcUNhWHdwUFBRODJDY0Fvd1pnRDB0aHVqQjdwTExDUUhXSzgyZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:01:55+00:00", "published_display": "11 May 2024 15:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOMXMtR3pjbUZYaXNLT2JhRXVqekczdFhBc0lFbjFubzU5V1hYeHZSZzJldmlvX19WTVE4Ti12a0RlX2xscHRvdlhVdUZ3aHZLNF9DNFRfV2s4TG82VFduT3U0SjdxV0hHZ0RCNG14SnBCYnlOeDVNeTZfV1ZrMmphSDljMA?oc=5", "source_name": "Market source", "published_at": "2024-04-18T07:00:00+00:00", "published_display": "18 Apr 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Biopharma on the path to validating traditional medicine for the modern world", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQmxKSmtRcWtiMkxUTEtoem9tZWlQaUxDWHdrblVPbzd1X05OUGdTUmZoN2FhX0VhNUtPdTNsektJVkxvTC1PYXZZTGt1SmVRY2JaOUh6eklmUGlFcThVbkpTeTZHT0oyRzROa1VwbWRnTGFQRFRtZ2x4Mkh0NFMtWjNIZXBpMjY3N1B1dFFzeVhVckNmbUVUTjE5RG9sLVppdGNrM0lzYU9FZEh4MmFkbXBxcHZrajc1VHVPbVZnU0I?oc=5", "source_name": "BioWorld News", "published_at": "2023-01-25T08:00:00+00:00", "published_display": "25 Jan 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for ABVC BIOPHARMA (ABVC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9jelVnekdXYzBxUk9hMTJXR1RqRjVMeDg0WVIzbWhFVk9rZ090d1U0bnZRdXVsb19kVXdBSDZTclRPeURKMHp2SHFwdnM3cFdGUTV6UElrTDFfcUE3T0pjamtmdWdLTFYzMzZCSVNjOExiaEM4YXBKRg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-11-11T18:11:34+00:00", "published_display": "11 Nov 2022 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC BioPharma (ABVC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5PTWtlLVVYbGozQzlSOE5IUzk3QmdzMFRQZ2kyWXBNYXQ2RUZXRklHNFFEMHViU19taHl0Y0M0MVRoYUlDSmNXRi1sT0lvOFFDdFdYU3cwNlB5dw?oc=5", "source_name": "MarketBeat", "published_at": "2021-09-14T21:04:03+00:00", "published_display": "14 Sep 2021 21:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abvc Biopharma Stock Price Forecast. Should You Buy ABVC?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE1oUFVxeHllSW81dFBIbHNYT0p2SlNkQjVuYzIyYWVDY2dMaWpIX1liaktOS2ZkSVNwVlF2YW1oVndsRGVmclJKXw?oc=5", "source_name": "StockInvest.us", "published_at": "2021-08-12T16:46:56+00:00", "published_display": "12 Aug 2021 16:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVC Stock Price and Chart \u2014 NASDAQ:ABVC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9BYkZiNXR0VGVWUDdsUkdhTkFTQVdlREljUkFEbUdHa3Rzc3BOcVBwblY5aG9SY1NXTlY3TnI3dUJfOVI4MnlMXzJKUWgwbjcyZ3p5UzF0U0g1eGF5?oc=5", "source_name": "TradingView", "published_at": "2021-08-04T10:05:36+00:00", "published_display": "04 Aug 2021 10:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 48, "sentiment_summary": {"positive": 8, "negative": 9, "neutral": 31, "score": 49, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 12.65, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 7.56, "count": 16}, {"event": "guidance", "label": "Guidance", "weight": 2.55, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 1.51, "latest_week": "2026-07-10", "one_week_move": -16.1, "four_week_move": 26.9, "twelve_week_move": 14.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.170295, "market_dynamics_buy_signal": false, "relative_strength": -39.208183, "fair_value_gap": 5.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 40.3715, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-16.1% over one week, +26.9% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 9}, {"label": "Market source", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 4}, {"label": "Intellectia AI", "count": 3}, {"label": "Benzinga", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "TradingView \u2014 Track All Markets", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 16}, {"label": "Guidance", "count": 4}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "49/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-16.1% over one week, +26.9% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "ABVC BioPharma (ABVC) replaces auditor and reiterates going-concern language"}], "updated_at": "2026-07-17T10:44:48.066261+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}